Embecta Corp. is a global medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. The Company has a portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It also sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. It sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It also sells safety insulin syringes. It distributes its products through a variety of channels, including retail, hospitals and pharmacies.
Hohe Gewinnwachstumsrate
Das Nettoeinkommen des Unternehmens führt die Branche an, das letzte Jahres Einkommen betrug insgesamt 1.08B USD.
Hohe Dividende
Das Unternehmen ist ein Hochdividendenzahler, mit dem neuesten Dividendenauszahlungsverhältnis von 38.36%.
Unterbewertet
Die aktuelle PE1 des Unternehmens liegt bei 1.752, im niedrigen 3-Jahres-Perzentilbereich.
Institutionelle Verkäufe
Die neuesten institutionellen Bestände sind 59.40M Aktien, was einen Rückgang von 7.24% im Vergleich zum Vorquartal darstellt.
Gehalten von Donald Yacktman
Star-Investor Donald Yacktman1 hält 9.87M2 Aktien dieses Unternehmens.